Professor Ali Shamseddine

Director of Gastrointestinal / Genitourinary Cancer Program, Basile Cancer Institution at the American University of Beirut

Lifetime Achievement Regional Track

Prof. Shamseddine is currently a Professor of Clinical Medicine and Director of the Gastrointestinal/ Genitourinary Cancer Program of the Naef K. Basile Cancer Institute at the American University of Beirut (AUB), where he has also served as Director of the Tumor Registry and Data Management Unit since 2014. He is Founder and Chair of the Advisory Board of Arab Collaborative Hematology-Oncology Group (ACHOG). He received his training at the American University of Beirut and he is a fellow of the Royal College of Physician in London.

Prof. Shamseddine’s previous positions include Head of the Hematology/Oncology Division from 2000-2017 and Chair of the hospital committee on cancer 1997-2011. He was appointed to the position of Vice President of the National Cancer Registry (NCR) from 2005-2010, and served as WHO advisor in epidemiology during 2013-2016. He also served as president of the Lebanese Society of Medical Oncology (LSMO, 2006-2008) and chair of European Arab Society of Oncology Prostatic Group in Lebanon (2010-2013).

He chaired the prostatic cancer session at the European School of Oncology (ESO) in 2016, 2017 and 2018, and was awarded the title of Faculty Member of the College of the ESO, Milano from 2020- present. He is a member of the scientific committee and active faculty of the World Gastrointestinal Cancer Conference (ESMO) from 2017 to 2018. In April 2018 he was nominated by ASCO to serve on an expert panel charged with developing clinical guidelines for treatment of advanced stage colorectal cancer.

Prof. Shamseddine has published more than 250 papers in peer-reviewed journals, and a book reporting the trends in cancer at AUB over 20 years (1983–2003). His research interests include epidemiology of cancer in Lebanon and the region, gastro-intestinal and prostatic cancers. His ongoing clinical research includes studying the outcome of chemo-immunotherapy with radiation therapy in GI cancers.